Table of Contents Table of Contents
Previous Page  629 / 812 Next Page
Information
Show Menu
Previous Page 629 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S625

subgroup. Health care costs in the high symptom severity subgroup

were significantly higher than those of the low symptom severity

subgroup (

P

< 0.001).

Conclusions

Our findings exhibit the necessity for subgroup-

specific treatment services for improving pain management and

reducing health care costs in the elderly.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1846

EV862

Ziconotide and amnesia: A case report

S. Marini

1 ,

, V. Lalli

2

, A. Costantini

2

, F. Gambi

1

1

University G. d’Annunzio, neurosciences and imaging, Chieti, Italy

2

SS Annunziata hospital, health urgent and emergency care, Chieti,

Italy

Corresponding author.

Introduction

Ziconotide is a new class of non-opioid analgesic

that selectively blocks the neuron-specific (N-type), voltage-gated

calcium channels, preventing the release of substance P and calci-

tonin gene-related peptide.

Methods

A literature search was conducted in September 2015

using Pubmed and Scopus databases. No articles speaking about the

direct correlation between ziconotide and amnesia were found.

Discussion

A 56-year-old female patient, in treatment with

ziconotide for chronic phantom pain syndrome, reported amnesia

and dysgeusia symptoms. No psychiatric pathologies were diag-

nosed except for the high anxiety state correlated to the amnesia

for recent events. The ziconotide treatment was reduced from 2,4

g/day to 1,5 g/day. Clonazepam was prescribed to treat the

anxiety state. The subject clinical conditions did not require hospi-

talization.

Conclusions

It is recommended that patients in treatment with

ziconotide be monitored for changes in mood, suicidality ideation,

thoughts or consciousness. Ziconotide could have serious neuro-

logical or psychiatric signs/symptoms

( Table 1 ).

Amnesia is a rare

side effect of intrathecal administration of ziconotide. Severe psy-

chiatric adverse effects may require ziconotide discontinuation,

treatment with psychotropic agents and/or acute hospitalization.

Table 1

Psychiatric disorders

Nervous system disorders

Hallucinations

Dysgeusia

Delusions

Dizziness

Confusional state

Dysarthria

Anxiety

Ataxia

Insomnia

Nystagmus

Cognitive disorder

Areflexia

Mood disorder

Burning sensation

Suicidality ideation

Hypoaesthesia, paraesthesia

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1847

EV863

Psychiatric disorders in patients with

atypical facial pain

V. Medvedev

1 ,

, V. Frolova

1

, Y. Fofanova

1

, A. Drobyshev

2

1

People’s Friendship university of Russia, Chair of psychiatry-

psychotherapy and psychosomatic pathology, Moscow, Russia

2

Moscow State university of medicine and dentistry, Chair of

maxillofacial and plastic surgery, Moscow, Russia

Corresponding author.

Objective

Maxillofacial surgeons and dentists often (up to 10%)

deal with the phenomenon of atypical facial pain (AFP) – painful

condition of maxillofacial area without clear organic pathology.

Psychiatric studies of this disorder are almost lacking.

Aim

The aim of this study was to define psychopathological dis-

orders in patients with AFP and to set up psychopharmacological

treatment strategies.

Methods

The study used clinical psychopathological and psycho-

metric (Pain measurement scales: Brief Pain Inventory, VAS, Pain

Catastrophizing Scale) methods. We included patients with AFP

examined in the clinic in December 2014 - September 2015.

Results

Study sample consists of 54 patients with AFP: 45

women (83.3%), 9 men (16.7%), 18-70 years old (39.5

±

14.7 years).

In 67.8% of patients (33 women, 4 men), AFP was associated

with affective disorders; among them, recurrent major depres-

sive disorder was verified in 9.2% (4 women, 1 men), single

depressive episode – in 33.6% (15 women, 3 man), bipolar II

depression – in 3.6% (2 women), cyclothymic disorder – in 7.1%

(4 women), dysthymia – in 14.3% (8 women). In 10.8% of patients

(6 women), AFP was considered as a symptom of somatoform

pain disorder. In 21.4% (6 women, 5 men), AFP was related with

schizotypal personality disorder. Psychopharmacological agents

used were SSRIs (fluvoxamine, escitalopram), SNRIs (venlafaxine,

duloxetine), agomelatine and antipsychotics (quetiapine, amisul-

pride, alimemazine). The pain subsides in 87,04% of patients and

the severity of pain decreased in 12.96% of patients.

Conclusion

Patients with AFP should be examined by psychia-

trist in order to determine psychopathological disorders and to

elaborate psychopharmacological treatment strategies.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1848

EV864

Psychosemantics of pain in patients

with coronary artery disease

E. Pervichko

1 ,

, Y . Z

inchenko

1 , L. P

ak

2

1

Lomonosov Moscow State university, faculty of psychology,

Moscow, Russia

2

Moscow State university of medicine and dentistry, faculty of

general medicine, Moscow, Russia

Corresponding author.

Introduction

It is known for a fact that a number of psychological

factors may affect heart pain perception in patients with coronary

artery disease (CAD). However, psychosemantics of pain in CAD

patients was hardly ever explored.

Objective

To study the features of pain psychosemantics in CAD

patients.

Methods

There were applied McGill Pain Questionnaire

(Melzack, 1975); the psychosemantic technique “Classifica-

tion of sensations” (Tkhostov, Efremova, 1989); the 20-item

Toronto Alexithymia Scale (Bagby, Taylor, Parker, 1994); and

State-Trait Anxiety Inventory (Spielberger et al., 1983). Fifty-four

CAD patients took part in the study, the mean age was 55.9

±

7.6

years. CAD duration was 5.8

±

2.6 years.

Results

CAD patients with the high level of trait anxiety (28%)

choose greater variety of descriptors for pain definition, reveal-

ing an impaired ability to differentiate between emotional states

and physical sensations. They show higher scale values for McGill

Pain Questionnaire. Patients with high indices of alexithymia (31%)

require significantly fewerwords for descriptionof painful anddan-

gerous perceptions within the “Classification of sensations”. This

may testify to a certain bafflement in verbal description of the pain.

With that, intensity of alexithymia does not correlate significantly

with the high level of state and trait anxiety (

P

> 0.05). The method

of “Classification of sensations” revealed that patients with trait

anxiety, as well as those with alexithymia, define the pain with